反复输尿管镜治疗上尿路尿路上皮癌的并发症:保肾手术的代价
该研究回顾性分析了67例接受保守内镜治疗的上尿路尿路上皮癌(UTUC)患者,共268次输尿管镜(URS)手术。47%患者发生至少一种并发症,5年任何并发症和重大并发症的累积发生率分别为62%和14%。URS次数是任何并发症和输尿管狭窄(US)的唯一显著预测因素。
要点
- 反复URS是并发症和输尿管狭窄的独立预测因素
- 5年任何并发症累积发生率为62%,重大并发症为14%
- 6次URS后输尿管狭窄预测风险达22.7%
核心结论
- UTUC保守治疗与主要为低级别并发症的累积风险相关
- 延长内镜随访可能增加部分患者输尿管狭窄的风险
- 研究结果支持充分的患者咨询和个体化监测计划
研究设计与样本
- 回顾性队列研究,纳入67例接受保守内镜治疗的UTUC患者
- 共268次输尿管镜手术(2015-2025年),来自高容量三级中心
- 并发症从首次URS至末次随访通过病历回顾和患者访谈收集,按Clavien-Dindo分级
主要发现
- 32例(47%)发生至少一种并发症
- Clavien-Dindo I-II级和IIIa-b级事件分别占并发症的87%和13%
- 12例(18%)出现内镜下输尿管狭窄证据,其中3例(25%)内镜治疗,2例(16%)最终需根治性肾输尿管切除术
- 5年任何并发症和重大并发症(Clavien-Dindo ≥3)累积发生率分别为62%(95%CI 43-75)和14%(95%CI 2-25)
- 单变量分析中,URS次数是任何并发症(OR 1.41/次,P=0.012)和输尿管狭窄(OR 1.20/次,P=0.042)的唯一显著相关变量
关键数值与推荐
- 6次URS后输尿管狭窄预测风险为22.7%
- 超过50个月,总体队列平均eGFR下降>20 mL/min/1.73 m²
- 未行RNU或因输尿管狭窄或肾积水需干预的患者平均下降仅约10 mL/min/1.73 m²
临床怎么用
- 对接受保守内镜治疗的UTUC患者应告知反复URS的累积并发症风险
- 根据URS次数个体化制定监测计划,警惕输尿管狭窄的发生
- 关注肾功能变化,尤其需干预输尿管狭窄或肾积水的患者
局限性
- 回顾性研究设计
- 单中心高容量三级中心数据,外推性受限
- 样本量较小(67例患者)
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the safety profile of, and identify predictors of complications in patients undergoing, endoscopic conservative upper tract urothelial carcinoma (UTUC) management at a high-volume tertiary centre. METHODS: We retrospectively reviewed 67 patients treated conservatively for UTUC, undergoing a total of 268 ureteroscopy (URS) procedures (2015-2025). Complications were collected via chart review and patient interviews from the first URS to last follow-up and graded according to the Clavien-Dindo classification. Univariable logistic regression was used to assess predictors of complications and ureteral stenosis (US). Cumulative incidence plots depicted time-to-complication events. Renal function was evaluated using serial estimated glomerular filtration rate measurements and analysed through individual trajectories and locally estimated scatterplot smoothed trends. RESULTS: The median number of URS per patient was three (interquartile range 2-5). At least one complication occurred in 32 patients (47%). Clavien-Dindo I-II and IIIa-b events accounted for 87% and 13% of complications, respectively. Twelve patients (18%) developed endoscopic evidence of US; of these, three (25%) were treated endoscopically and two (16%) ultimately required radical nephroureterectomy. The 5-year cumulative incidence of any and major complications (Clavien-Dindo ≥ 3) was 62% (95% confidence interval 43-75) and 14% (95% confidence interval 2-25), respectively. On univariable analysis, the number of URS was the only variable significantly associated with both any complication (odds ratio 1.41 per URS, P = 0.012) and US (odds ratio 1.20 per URS, P = 0.042). The predicted risk of US reached 22.7% after six URS. Over 50 months, mean estimated glomerular filtration rate declined by >20 mL/min/1.73 m2 in the overall cohort, whereas the mean decline was limited to ~10 mL/min/1.73 m2 in patients who did not undergo RNU or require intervention for US or hydronephrosis. CONCLUSIONS: Conservative management of UTUC is associated with a cumulative risk of mostly low-grade complications. Prolonged endoscopic follow-up may increase the likelihood of US in a subset of patients. These findings support informed patient counselling and individualized surveillance planning.
引用
- Scilipoti P, Occhi A, Robesti D, et al. Complications following repeated ureteroscopy for UTUC: The price to pay for nephron-sparing surgery. BJU Int. 2026. PMID: 42219908. doi:10.1111/bju.70331
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。